A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma Read more
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma Read more
A Prospective, Non-Interventional, Multinational, Observational Study With Isatuximab In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM) Read more
A Disease Registry Encompassing The Care Of Patients With Multiple Myeloma On Panobinostat (RECOMM) Read more
A Phase 2, Multicohort Open-Label Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA In Subjects With Multiple Myeloma (CARTITUDE 2) Read more
A Phase 1/2, Multicenter, Dose-Escalation And Expansion Study Of Combination Therapy With Venetoclax, Daratumumab And Dexamethasone (With And Without Bortezomib) In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
Clinical Grade Molecular Profiling Of Patients With Multiple Myeloma And Related Plasma Cell Malignancies Read more
